CDC logo, Safer Healthier People CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us




Hydrazine, 1,2 - dimethyl -

RTECS #: MV2625000

CAS #: 540-73-8

UPDATE: May 2009 MW: 60.12 MF: C2H8N2


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. MUTATION DATA:
  3. REPRODUCTIVE EFFECTS DATA:
  4. TUMORIGENIC DATA:
  5. ACUTE TOXICITY DATA:
  6. OTHER MULTIPLE DOSE DATA:
  7. REVIEWS:
  8. STANDARDS AND REGULATIONS:
  9. NIOSH DOCUMENTATION AND SURVEILLANCE:
  10. STATUS IN FEDERAL AGENCIES:
  11. REFERENCES:

SYNONYMS:

  1. 1,2 - Dimethyl - hydrazine
  2. 1,2 - Dimethylhydrazin (German)
  3. 1,2 - Dimethylhydrazine
  4. Hydrazomethane
  5. N,N' - Dimethylhydrazine
  1. RCRA waste number U099
  2. SDMH
  3. Symetryczna dwumetylohydrazyna (Polish)
  4. sym - Dimethylhydrazine


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE 		DOSE REFERENCE
cytogenetic analysis oral
mouse 		12 mg/kg JJIND8 71,133,1983
cytogenetic analysis subcutaneous
mouse 		15 mg/kg VOONC* 43,623,1997
cytogenetic analysis subcutaneous
rat 		160 mg/kg/4 day/2 week- intermittent EMMUEG 45,8,2005
cytogenetic analysis intraperitoneal
rat 		120 mg/kg/6 week EMMUEG 44,113,2004
DNA adduct hamster lung 2 mmol/L MUREAV 173,157,1986
DNA adduct human lung 1,290 µmol/L CNREA8 37,2309,1977
DNA adduct human fibroblast 20 µmol NTIS** AD-A092-249
DNA adduct rat other cell types 100 µmol/L TCMUD8 1,3,1980
DNA damage oral
mouse 		5,700 µg/kg MUREAV 54,39,1978
DNA damage subcutaneous
mouse 		56,200 µg/kg MUREAV 54,39,1978
DNA damage intraperitoneal
mouse 		20 mg/kg MUTAEX 16,39,2001
DNA damage parenteral
rat 		210 mg/kg PAACA3 24,82,1983
DNA damage oral
rat 		20 mg/kg ENMUDM 4,667,1982
DNA damage intraperitoneal
rat 		10,200 µg/kg CNREA8 41,3967,1981
DNA damage rat liver 300 µmol/L SinJF# 26OCT1982
DNA damage subcutaneous
rat 		160 mg/kg/2 week- intermittent TCMUD8 22,183,2001
DNA damage subcutaneous
rat 		40 mg/kg EMMUEG 45,8,2005
DNA damage intraperitoneal
rat 		120 mg/kg/6 week EMMUEG 44,113,2004
DNA damage subcutaneous
rat 		180 mg/kg/6 week- intermittent BPBLEO 30,569,2007
DNA inhibition oral
mouse 		200 mg/kg MUREAV 46,305,1977
DNA inhibition intraperitoneal
mouse 		60 mg/kg JTEHD6 13,117,1984
DNA repair Bacillus subtilis 6 mg/disc MUREAV 97,1,1982
DNA repair Escherichia coli 250 µg/disc JJIND8 62,873,1979
unscheduled DNA synthesis human lung 100 µL/L NTIS** AD-A041-973
unscheduled DNA synthesis subcutaneous
mouse 		560 mg/kg/28 week- intermittent CNREA8 43,2545,1983
unscheduled DNA synthesis intraperitoneal
mouse 		200 mg/kg JTEHD6 13,117,1984
host-mediated assay mouse
Escherichia coli 		50 µmol/kg MUREAV 148,1,1985
host-mediated assay intraperitoneal
mouse 		30 mg/kg MUREAV 564,1,2004
host-mediated assay intraperitoneal
mouse 		100 mg/kg/10 week- intermittent MUREAV 564,1,2004
mutation in microorganisms Bacillus subtilis 25 µg/plate (-enzymatic activation step) CALEDQ 12,287,1981
mutation in microorganisms mouse lymphocyte 10 µL/L (+enzymatic activation step) NTIS** AD-A041-973
mutation in microorganisms Salmonella typhimurium 25 µg/plate (+enzymatic activation step) CALEDQ 12,287,1981
micronucleus test oral
mouse 		720 µg/kg MUREAV 368,115,1996
micronucleus test intraperitoneal
mouse 		10 mg/kg EMMUEG 17,155,1991
micronucleus test oral
rat 		3,320 µg/kg MUREAV 368,115,1996
gene conversion and mitotic recombination Saccharomyes cerevisiae 200 mmol/L NATWAY 54,251,1967
mutation in mammalian somatic cells hamster lung 100 µmol/L PAACA3 24,93,1983
mutation in mammalian somatic cells mouse lymphocyte 5 mmol/L/24 hour NTIS** AD-A075-605
mutation in mammalian somatic cells subcutaneous
rat 		100 mg/kg/5 week- intermittent CRNGDP 22,315,2000
morphological transform hamster embryo 100 µg/L IJCNAW 19,642,1977
morphological transform human fibroblast 230 µmol/L CALEDQ 29,265,1985
morphological transform oral
mouse 		30 mg/kg/8 day- intermittent CNREA8 49,1236,1989
morphological transform intraperitoneal
rat 		500 µmol/kg CALEDQ 20,207,1983
morphological transform oral
rat 		500 µmol/kg CALEDQ 20,207,1983
other mutation test systems subcutaneous
mouse 		560 mg/kg/28 week- intermittent CNREA8 43,2545,1983
phage inhibition capacity Escherichia coli 9,400 mg/L CNREA8 41,532,1981
sister chromatid exchange hamster ovary 130 µmol/L MUREAV 68,351,1979
sister chromatid exchange intraperitoneal
mouse 		270 µmol/kg TCMUD8 9,219,1989
sister chromatid exchange intraperitoneal
mouse 		20 mg/kg MUTAEX 2,441,1987
sperm morphology subcutaneous
mouse 		15 mg/kg VOONC* 43,623,1997


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
rat 		lowest published toxic dose: 100 mg/kg (6-15 day pregnant) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) JTEHD6 13,125,1984


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
implant
rabbit 		lowest published toxic dose: 2 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors

Tumorigenic: Tumors at site of application 		CNREA8 35,2292,1975
intraperitoneal
mouse 		lowest published toxic dose: 25 mg/kg/24 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors 		TXAPA9 72,313,1984
intraperitoneal
rat 		lowest published toxic dose: 260 mg/kg/13 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors 		CALEDQ 19,1,1983
oral
mouse 		lowest published toxic dose: 12,500 µg/kg/24 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors 		TXAPA9 72,313,1984
oral
rat 		lowest published toxic dose: 120 mg/kg/4 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors

Eye: Other eye effects 		AJCNAC 30,176,1977
oral
rat 		lowest published toxic dose: 160 mg/kg/2 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		CALEDQ 168,23,2001
oral
rat 		lowest published toxic dose: 1,750 mg/kg/2 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Endocrine: Thyroid tumors 		CALEDQ 168,23,2001
parenteral
rat 		lowest published toxic dose: 160 mg/kg/16 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors 		PAACA3 21,67,1980
rectal
mouse 		lowest published toxic dose: 360 mg/kg/18 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors 		FEPRA7 34,827,1975
subcutaneous
hamster 		lowest published toxic dose: 340 mg/kg/17 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Behavioral: Ataxia

Gastrointestinal: Hypermotility, diarrhea 		EXMPA6 27,19,1977
subcutaneous
monkey 		lowest published toxic dose: 400 mg/kg/2 year- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors 		JJCREP 83,584,1992
subcutaneous
monkey 		lowest published toxic dose: 608 mg/kg/2 year- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Reproductive: Tumorigenic effects: Uterine tumors 		JJCREP 83,584,1992
subcutaneous
mouse 		lowest published toxic dose: 200 mg/kg/10 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Gastrointestinal: Colon tumors 		JJIND8 63,1081,1979
subcutaneous
mouse 		toxic dose : 300 mg/kg/20 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors

Reproductive: Tumorigenic effects: Uterine tumors 		JNCIAM 52,999,1974
subcutaneous
mouse 		lowest published toxic dose: 160 mg/kg/20 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors

Reproductive: Other reproductive system tumors 		VOONC* 43,321,1997
subcutaneous
rat 		lowest published toxic dose: 90 mg/kg/28 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Eye: Other eye effects

Gastrointestinal: Colon tumors 		BIMDB3 32,41,1980
subcutaneous
rat 		toxic dose : 120 mg/kg/12 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors 		NASDA6 32,270,1981
subcutaneous
rat 		toxic dose : 20 mg/kg Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Tumors

Gastrointestinal: Colon tumors 		GANNA2 74,493,1983
subcutaneous
rat 		toxic dose : 200 mg/kg/10 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors

Kidney, Ureter, and Bladder: Kidney tumors 		CRNGDP 3,1097,1982
subcutaneous
rat 		toxic dose : 80 mg/kg/4 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors 		CRNGDP 6,637,1985
subcutaneous
rat 		toxic dose : 300 mg/kg/11 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors 		GASTAB 81,475,1981
subcutaneous
rat 		toxic dose : 42 mg/kg/28 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Skin and Appendages: Tumors

Gastrointestinal: Tumors 		BIMDB3 32,41,1980
subcutaneous
rat 		toxic dose : 420 mg/kg/28 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Tumors

Kidney, Ureter, and Bladder: Kidney tumors 		CRNGDP 4,1175,1983
subcutaneous
rat 		toxic dose : 200 mg/kg/20 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors

Gastrointestinal: Colon tumors 		DICRAG 23,137,1980
subcutaneous
rat 		toxic dose : 400 mg/kg/10 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors 		LANCAO 2,1030,1980
subcutaneous
rat 		lowest published toxic dose: 105 mg/kg/24 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Other changes 		CALEDQ 148,215,2000
subcutaneous
rat 		toxic dose : 160 mg/kg/2 week Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Other changes 		CALEDQ 154,121,2000
subcutaneous
rat 		lowest published toxic dose: 80 mg/kg/4 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors 		CRNGDP 21,173,2000
subcutaneous
rat 		lowest published toxic dose: 60 mg/kg/7 day- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors 		CRNGDP 21,2255,2000
subcutaneous
rat 		lowest published toxic dose: 100 mg/kg/5 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors 		CRNGDP 22,315,2000
subcutaneous
rat 		lowest published toxic dose: 105 mg/kg/5 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors 		CALEDQ 138,27,1999
subcutaneous
rat 		lowest published toxic dose: 160 mg/kg/4 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors 		MUREAV 506-507,129,2002
subcutaneous
rat 		lowest published toxic dose: 420 mg/kg/20 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Tumors 		CALEDQ 147,125,1999
subcutaneous
rat 		lowest published toxic dose: 160 mg/kg/2 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors 		TCMUD8 22,183,2001
subcutaneous
rat 		lowest published toxic dose: 80 mg/kg/3 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors

Liver: Tumors 		JTSCDR 27,57,2002
subcutaneous
rat 		lowest published toxic dose: 300 mg/kg/15 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors

Tumorigenic: Increased incidence of tumors in susceptible strains 		PHMREP 47,133,2003
subcutaneous
rat 		lowest published toxic dose: 160 mg/kg/2 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Tumorigenic: Increased incidence of tumors in susceptible strains 		TXAPA9 194,132,2004
subcutaneous
rat 		lowest published toxic dose: 80 mg/kg/4 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors

Tumorigenic: Increased incidence of tumors in susceptible strains 		CALEDQ 202,11,2003
subcutaneous
rat 		lowest published toxic dose: 260 mg/kg/21 day- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Colon tumors

Skin and Appendages: Tumors 		FCTOD7 44,271,2006
subcutaneous
rat 		lowest published toxic dose: 180 mg/kg/6 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors 		BPBLEO K61


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
inhalation
rat 		lowest published lethal concentration: 280 ppm/4 hour Eye: Other eye effects

Behavioral: Convulsions or effect on seizure threshold

Lung, Thorax, or Respiration: Dyspnea 		AMIHAB 12,609,1955
intramuscular
hamster 		lethal dose (50 percent kill): 95 mg/kg N/R ARZNAD 19,1891,1969
intraperitoneal
mouse 		lethal dose (50 percent kill): 35 mg/kg N/R MEPAAX 24,71,1973
intraperitoneal
rat 		lethal dose (50 percent kill): 163 mg/kg N/R MEPAAX 24,71,1973
intravenous
dog 		lethal dose (50 percent kill): 100 mg/kg N/R MEPAAX 24,71,1973
intravenous
mouse 		lethal dose (50 percent kill): 29 mg/kg N/R MEPAAX 24,71,1973
intravenous
rat 		lethal dose (50 percent kill): 176 mg/kg N/R MEPAAX 24,71,1973
oral
mouse 		lethal dose (50 percent kill): 36 mg/kg N/R MEPAAX 24,71,1973
oral
rat 		lethal dose (50 percent kill): 100 mg/kg N/R NATWAY 54,285,1967
oral
rat 		lowest published toxic dose: 10 mg/kg Gastrointestinal: Necrotic changes FCTOD7 40,801,2002
oral
rat 		lowest published toxic dose: 25 mg/kg Nutritional and Gross Metabolic: Weight loss or decreased weight gain FCTOD7 40,801,2002
subcutaneous
mouse 		lethal dose (50 percent kill): 24 mg/kg N/R TOLED5 8,87,1981
subcutaneous
mouse 		lowest published toxic dose: 80 mg/kg Gastrointestinal: Other changes JJIND8 93,1534,2001
subcutaneous
rat 		lethal dose (50 percent kill): 220 mg/kg N/R XENOBH 3,271,1973
subcutaneous
rat 		lowest published toxic dose: 40 mg/kg Liver: Tumors

Gastrointestinal: Colon tumors 		TXAPA9 227,136,2008


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lowest published toxic dose: 136 mg/kg/20 week- intermittent Gastrointestinal: Colon tumors CRNGDP 24,527,2003
intraperitoneal
rat 		lowest published toxic dose: 120 mg/kg/6 week- intermittent Gastrointestinal: Other changes EMMUEG 44,113,2004
intraperitoneal
rat 		lowest published toxic dose: 120 mg/kg/6 week- intermittent Gastrointestinal: Colon tumors

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Catalases

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases 		EMMUEG 44,113,2004
subcutaneous
rat 		lowest published toxic dose: 300 mg/kg/15 week- intermittent Gastrointestinal: Other changes

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects

Biochemical: Metabolism (intermediary): Lipids including transport 		PHMREP 47,133,2003
subcutaneous
rat 		: 160 mg/kg/2 week- intermittent Gastrointestinal: Colon tumors FCTOD7 44,877,2006
subcutaneous
rat 		lowest published toxic dose: 80 mg/kg/4 week- intermittent Gastrointestinal: Other changes

Gastrointestinal: Colon tumors

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation 		TXAPA9 214,290,2006
subcutaneous
rat 		lowest published toxic dose: 180 mg/kg/6 week- intermittent Gastrointestinal: Colon tumors BPBLEO 30,569,2007
subcutaneous
rat 		lowest published toxic dose: 480 mg/kg/16 week- intermittent Gastrointestinal: Colon tumors

Nutritional and Gross Metabolic: Weight loss or decreased weight gain

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects 		TOLED5 171,10,2007
subcutaneous
rat 		lowest published toxic dose: 60 mg/kg/5 day- intermittent Gastrointestinal: Other changes CRNGDP 24,491,2003


REVIEWS:

ORGANIZATION STANDARD
REFERENCE
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 4,145,1974
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 71,947,1999
International Agency for Research on Cancer (IARC) Cancer Review Human No Adequate Data IMEMDT 4,145,1974
International Agency for Research on Cancer (IARC) Cancer Review Human No Adequate Data IMEMDT 71,947,1999
International Agency for Research on Cancer (IARC) Cancer Review Group 2A IMEMDT 71,947,1999
TOXICOLOGY REVIEW
MUREAV 39,111,1977
TOXICOLOGY REVIEW
MUTAEX 15,431,2000
TOXICOLOGY REVIEW
MUREAV 588,88,2005
TOXICOLOGY REVIEW
EMMUEG 44,26,2004
TOXICOLOGY REVIEW
FCTOD7 44,1699,2006
TOXICOLOGY REVIEW
MUREAV 627,10,2007
TOXICOLOGY REVIEW
BCLPT* 96,131,2005
TOXICOLOGY REVIEW
JTPAE7 19,1,2006
TOXICOLOGY REVIEW
MUREAV 658,68,2008
TOXICOLOGY REVIEW
MUREAV 566,191,2004
TOXICOLOGY REVIEW
HTOPA* 1,501,2002


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE
Occupational Exposure Limit - HUNGARY ceiling concentration 1.2 mg/m3, Carcinogen, SEP2000
Occupational Exposure Limit - SWEDEN Group B Carcinogen, JUN2005
Occupational Exposure Limit - SWITZERLAND MAK- week 0.5 ppm (1.2 mg/m3), Skin, Carcinogen, DEC2006


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO HYDRAZINES-air Carcinogen ceiling concentration 0.03 ppm/120 minute NIOSH* DHHS #92-100,1992


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE
ATSDR TOXICOLOGY PROFILE (NTIS** PB/98/101025/AS)
EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; Host-mediated assay
EPA GENETOX PROGRAM 1988, Positive: E coli polA without S9
EPA GENETOX PROGRAM 1988, Negative: Histidine reversion-Ames test
EPA GENETOX PROGRAM 1988, Inconclusive: SHE-clonal assay; Mammalian micronucleus
EPA GENETOX PROGRAM 1988, Inconclusive: S cerevisiae-homozygosis
Used as a high energy propellant for liquid fuelled rockets
On EPA IRIS database


REFERENCES:

CODEN
REFERENCE
AJCNAC American Journal of Clinical Nutrition. (American Soc. for Clinical Nutrition, Inc., 9650 Rockville Pike, Bethesda, MD 20814) V.2- 1954-
AMIHAB AMA Archives of Industrial Health. (Chicago, IL) V.11-21, 1955-60. For publisher information, see AEHLAU.
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
BCLPT* Basic & clinical pharmacology & toxicology (Copenhagen, Denmark : Nordic Pharmacological Society Oxford, UK : Distributed by Blackwell Munksgaard) V.94- 2004-
BIMDB3 Biomedicine. (Paris, France) V.18-34, 1973-81.
BPBLEO Biological and Pharmaceutical Bulletin. (Pharmaceutical Society of Japan, 2-12-15-201 Shibuya Shibuya-ku, Tokyo 150, Japan) V.16- 1993-
CALEDQ Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975-
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
DICRAG Diseases of the Colon and Rectum. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1958-
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987-
ENMUDM Environmental Mutagenesis. (New York, NY) V.1-9, 1979-87. For publisher information, see EMMUEG.
EXMPA6 Experimental and Molecular Pathology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1962-
FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982-
FEPRA7 Federation Proceedings, Federation of American Societies for Experimental Biology. (Bethesda, MD) V.1-46, 1942-87.
GANNA2 Gann. Japanese Journal of Cancer Research. (Tokyo, Japan) V.1-75, 1907-84. For publisher information, see JJCREP.
GASTAB Gastroenterology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1943-
HTOPA*
IJCNAW International Journal of Cancer. (International Union Against Cancer, 3 rue du Conseil- General, 1205 Geneva, Switzerland) V.1- 1966-
IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
JJCREP Japanese Journal of Cancer Research. (Elsevier Science Pub. BV, POB 211, 1000 AE Amsterdam, Netherlands) V.76- 1985-
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
JTEHD6 Journal of Toxicology and Environmental Health. (Hemisphere Pub., 1025 Vermont Ave., NW, Washington, DC 20005) V.1- 1975/76-
JTPAE7 Journal of Toxicologic Pathology. (Nihon Dokusei Byori Gakkai, editor, 3-25-8 Nishi- shinbashi, Minato-ku, Tokyo 105, Japan) V.1- 1988
JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976-
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823-
MEPAAX Medycyna Pracy. Industrial Medicine. (Ars-Polona, POB 1001, 00-068 Warsaw 1, Poland) V.1- 1950-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986-
NASDA6 Nagoya Shiritsu Daigaku Igakkai Zasshi. Journal of the Nagoya City University Medical Association. (Nagoya-shiritsu Daigaku Igakkai, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467, Japan) V.1- 1950-
NATWAY Naturwissenschaften. (Springer-Verlag, Heidelberger Platz 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.1- 1913-
NIOSH* National Institute of Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda.
NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information.
PAACA3 Proceedings of the American Association for Cancer Research. (Waverly Press, 428 E. Preston St., Baltimore, MD 21202) V.1- 1954-
PHMREP Pharmacological Research. (Academic Press, 24-28 Oval Rd. London NW1 7DX, UK) V.21- 1989-
SinJF# Personal Communication from J.F. Sina, Merck Institute for Therapeutic Research, West Point, PA 19486, Oct. 26, 1982
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980-
TOLED5 Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977-
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
VOONC* Voprosi oncologii (Questions of oncology. Journal of Petrov's Institute of Oncology, B. Zelenina str, 43a, Spb 197110, Russia) V.1- 1955-
XENOBH Xenobiotica. (Taylor & Francis Ltd., 4 John St., London WC1N 2ET, UK) V.1- 1971-

Used as a high energy propellant for liquid fuelled rockets

RTECS Compound Description:
   Tumorigen
   Mutagen
   Reproductive Effector
   Human Data

 Click Here for Additional Information about RTECS

NIOSH Home |  NIOSH Search  |  Site Index  |  Topic List |  Contact Us